医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

C.C.Medico Announces the Launch of Wrapping Foundation AirSkin®, the Cosmetic That Exquisitely Wraps You Like a Lovely Gift

2014年12月23日 AM02:30
このエントリーをはてなブックマークに追加


 

TOKYO

C.C.Medico.Co., Ltd. has developed AirSkin®, a wrapping foundation that exquisitely wraps your skin like a lovely gift with an attractive wrapping film. AirSkin® is not spread on like previous cosmetic products. It is a completely new type of cover-up foundation that uses a microns-thick skin-colored film that users apply to their skin.

YouTube “This is AirSkin ® (60 seconds)”

Although we at C.C.Medico have been involved in developing cover-up cosmetic products to hide blemishes, bruises, dullness, and surgical and natural scars, we were never able to develop a product that could completely cover these skin conditions using liquid or powder based cosmetics.

We discovered from a member of our testing group , that they would conceal tattoos using tape. This led us to move from developing spread-on foundation to engage in the development of an applied foundation.

Since this newly perfected AirSkin® is based on a method that transfers a microns-thick skin-colored film onto the user’s skin, it has several advantages over previous foundations. These include the ability to cover uniformly without blotches as well as greatly improved water resistance, scratch resistance, and durability.

Starting this Christmas, we will deliver AirSkin® – the product that will exquisitely wrap you like a dazzling gift – to the world.

WEB SHOP SANNA’S (Payment accepted in USD, EUR, BRL, and JPY)

In English

In Portuguese

In Spanish

[Company Overview]

Website

AirSkin Website

CONTACT

C.C.Medico Co.,Ltd.
Mayu Ishikawa, +81-3-5942-5536
ccmedico@me.com
fax:
+81-3-5542-5529

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Takeda Selects Four New Partners for Annual Global Corporate Social Responsibility (CSR) Program to Help Strengthen Health Systems in Low- and Middle-Income Countries
  • AnHeart Therapeutics Announces Formation of Scientific Advisory Board
  • Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 2 and Phase 3a for ARCT-154, Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern
  • Celltrion用于治疗COVID-19的单克隆抗体瑞丹维单抗(CT-P59)成为韩国食品药品安全部(MFDS)首个核准用于治疗COVID-19的药物
  • Celltrionのモノクローナル抗体治療薬、Regdanvimab(CT-P59)は、韓国食品医薬品安全庁(MFDS)からCOVID-19感染症治療薬として初めて承認された。